10-Q: Integrated BioPharma Reports Q3 2025 Results: Sales and Profitability Increase

Integrated BioPharma reports increased sales and profitability for the third quarter of 2025, driven by growth in both its Contract Manufacturing and Other Nutraceutical Businesses segments.

Summary

• Integrated BioPharma, Inc. reported its financial results for the quarter ended March 31, 2025.
• Net sales increased by 6.9% to $40.178 million for the nine months ended March 31, 2025, compared to $37.571 million for the same period in 2024.
• The Contract Manufacturing segment saw a 5% increase in net sales, while the Other Nutraceuticals segment increased by 2%.
• Operating income increased significantly to $1.431 million for the nine months ended March 31, 2025, compared to an operating loss of $0.151 million for the same period in 2024.
• Net income for the nine months ended March 31, 2025, was $986,000, compared to a net loss of $156,000 for the same period in 2024.
• Basic net income per common share was $0.03, compared to a loss of $0.01 in the previous year.
• The company paid off its Senior Credit Facility and entered into a new Loan Agreement with PNC Bank on April 15, 2025.
• Approximately 83% of consolidated net sales were derived from two customers.
• The company is managing the impact of inflation and tightened labor markets by striving to increase prices to customers.

Sentiment

Score: 7

Explanation: The sentiment is positive due to increased sales, improved profitability, and a new loan agreement. However, the customer concentration risk and inflationary pressures temper the overall outlook.

Positives

• Net sales increased by 6.9% to $40.178 million for the nine months ended March 31, 2025.
• Operating income increased significantly to $1.431 million for the nine months ended March 31, 2025.
• Net income for the nine months ended March 31, 2025, was $986,000, a significant improvement from the $156,000 loss in the same period last year.
• The company paid off its Senior Credit Facility and entered into a new Loan Agreement with PNC Bank on April 15, 2025.
• Profit margins increased from approximately 6.9% of net sales in the nine months ended March 31, 2024 to approximately 10.2% of net sales in the nine months ended March 31, 2025.

Negatives

• Approximately 83% of consolidated net sales were derived from two customers, highlighting customer concentration risk.
• The company faces challenges related to inflation and tightened labor markets, which could impact margins if price increases to customers are not timely.

Risks

• The company's reliance on two major customers poses a significant risk if either customer reduces their orders.
• Inflation and tightened labor markets could negatively impact margins if the company cannot timely increase prices to customers.
• Economic conditions, including tariffs and inflationary pressures, could impact consumer spending and reduce orders from significant customers.
• The loss of any significant customers or suppliers could have an adverse effect on the company's operations.

Future Outlook

The company is focusing its efforts to improve operational efficiency and reduce spending. Management believes that operations, together with the credit facilities in place, will support working capital requirements at least through May 14, 2026. The company will continue to focus on its core businesses and push forward in maintaining its cost structure in line with its sales and expanding its customer base. We believe that this focus will produce a reduction of the reliance on our two significant customers in our fiscal year ending June 30, 2025.

Management Comments

• We are focusing our efforts to improve operational efficiency and reduce spending that may have an impact on expense levels and gross margin.
• We will continue to focus on our core businesses and push forward in maintaining our cost structure in line with our sales and expanding our customer base.
• We believe that this focus will produce a reduction of the reliance on our two significant customers in our fiscal year ending June 30, 2025.

Industry Context

The nutraceutical industry is experiencing growth, and Integrated BioPharma is positioned to benefit from this trend. However, the company faces competition from other manufacturers and distributors. The company's ability to manage costs and maintain customer relationships will be critical to its success.

Comparison to Industry Standards

• It is difficult to compare Integrated BioPharma directly to industry standards without more specific information on its product mix and customer base.
• However, the company's gross margin of approximately 10.2% for the nine months ended March 31, 2025, is relatively low compared to some other nutraceutical companies.
• For example, Herbalife Nutrition Ltd. often reports gross margins in the range of 75-80%.
• Customer concentration is a risk factor that Integrated BioPharma needs to address to improve its long-term stability.
• Diversifying the customer base would reduce the impact of losing a major customer.

Related Party Transactions

• Warehouse and office facilities are leased from Vitamin Realty Associates, LLC (Vitamin Realty), which is 100% owned by the estate of the Company's former chairman, and a major stockholder and certain of his family members, who are the Co-Chief Executive Officers and directors of the Company.
• Rent expense and lease amortization costs for the three months ended March 31, 2025 and 2024 on this lease were $ 348 and $332 respectively, and for the nine months ended March 31, 2025 and 2024 were $ 1,000 and $974, respectively, and are included in cost of sales and selling and administrative expenses in the accompanying Condensed Consolidated Statements of Operations.
• As of March 31, 2025 and June 30, 2024, the Company had no current obligations to Vitamin Realty.
• Additionally, the Company has operating lease obligations of $689 and $1,289 with Vitamin Realty as noted in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2025 and June 30, 2024, respectively.

Stakeholder Impact

• Shareholders will likely view the improved financial performance positively.
• Employees may benefit from the company's improved financial stability.
• Customers may experience stable or improved product quality and service.
• Suppliers may benefit from increased orders and timely payments.
• Creditors may view the company as a lower credit risk due to its improved financial performance.

Next Steps

• The company will continue to focus on improving operational efficiency and reducing spending.
• The company will work to expand its customer base and reduce reliance on its two significant customers.
• The company will manage the impact of inflation and tightened labor markets by striving to increase prices to customers.

Key Dates

Keywords

financial results, nutraceuticals, contract manufacturing, sales, profitability, Integrated BioPharma, 10-Q